This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs. Peg-Intron plus Rebetol in Hepatitis C Virus (HCV) genotype 1-infected subjects who are either naive to treatment or who have previously failed treatment (non-responders).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
246
SC injection, weight based dosing, weekly, 48 weeks
Capsules, weight based dosing, Q12 hrs daily, 48weeks
Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
Hepatitis C Virus (HCV) RNA concentrations in the blood.
Time frame: 72 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
SC injection, weight based dosing, weekly, 48 weeks
Capsules, weight based dosing, Q12 hrs daily, 48weeks
Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
SC injection, weight based dosing, weekly, 48 weeks
Capsules, weight based dosing, Q12 hrs daily, 48weeks
Pfizer Investigational Site
Anaheim, California, United States
Pfizer Investigational Site
La Jolla, California, United States
Pfizer Investigational Site
La Jolla, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Pasadena, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, United States
...and 25 more locations